Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase inhibitors (TKIs) marked the advent of the era of precision medicine for non-small-cell lung cancer (NSCLC). First- and second-gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Santarpia, Mariacarmela, Liguori, Alessia, Karachaliou, Niki, Gonzalez-Cao, Maria, Daffinà, Maria Grazia, D’Aveni, Alessandro, Marabello, Grazia, Altavilla, Giuseppe, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571822/
https://www.ncbi.nlm.nih.gov/pubmed/28860885
http://dx.doi.org/10.2147/LCTT.S119644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571822/
https://www.ncbi.nlm.nih.gov/pubmed/28860885
http://dx.doi.org/10.2147/LCTT.S119644

Ejemplares similares